The metabolic syndrome. Beyond the insulin resistance syndrome

Pharmacological Research

Volumn 53, Issue 6, 2006, Pages 457-468

  Penno, Giuseppe ^a   Miccoli, Roberto ^a   Pucci, Laura ^a   Del Prato, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Inflammation; Insulin resistance; Metabolic syndrome; Visceral adiposity

Indexed keywords

GLUCOSE; INSULIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FACTORIAL ANALYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL;

BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 33646756191     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.03.010     Document Type: Article

References (92)

1. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
2. Balkau B., Charles M.A., Drivsholm T., Borch-Johnsen K., Wareham N., Yudkin J.S., and European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 28 (2002) 364-376
3. American College of Endocrinology. Insulin resistance syndrome (Position Statement). Endocr Pract 9 (2003) 240-252
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
5. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
6. Alberti K.G., Zimmet P., and Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
7. Despres J.P. Our passive lifestyle, our toxic diet, and the atherogenic/diabetogenic metabolic syndrome: can we afford to be sedentary and unfit?. Circulation 112 (2005) 453-455
8. Hanley A.J., Karter A.J., Festa A., D'Agostino Jr. R., Wagenknecht L.E., Savage P., et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes 51 (2002) 2642-2647
9. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2005) 2289-2304
10. DeFronzo R.A., and Ferranini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
11. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., and Lenfant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109 (2004) 433-438
12. Ferrannini E., and Balkau B. Insulin: in search of a syndrome. Diabet Med 19 (2002) 724-729
13. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., Pyorala K., and DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164 (2004) 1066-1076
14. Cruz M.L., Weigensberg M.J., Huang T.T., Ball G., Shaibi G.Q., and Goran M.I. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 89 (2004) 108-113
15. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., and Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139 10 (2003, Nov 18) 802-809
16. Liao Y., Kwon S., Shaughnessy S., Wallace P., Hutto A., Jenkins A.J., et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27 (2004) 978-983
17. Cheal K.L., Abbasi F., Lamendola C., McLaughlin T., Reaven G.M., and Ford E.S. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53 (2004) 1195-1200
18. Facchini F.S., Hua N., Abbasi F., and Reaven G.M. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 86 (2001) 3574-3578
19. Lind L., Berne C., and Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 13 (1995) 1457-1462
20. Lawlor D.A., Ebrahim S., May M., and Davey S.G. (Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol 159 (2004) 1013-1018
21. Edwards K.L., Austin M.A., Newman B., Mayer E., Krauss R.M., and Selby J.V. Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb 14 (1994) 1940-1945
22. Donahue R.P., Bean J.A., Donahue R.D., Goldberg R.B., and Prineas R.J. Does insulin resistance unite the separate components of the insulin resistance syndrome? Evidence from the Miami Community Health Study. Arterioscler Thromb Vasc Biol 17 (1997) 2413-2417
23. Meigs J.B., D'Agostino Sr. R.B., Wilson P.W., Cupples L.A., Nathan D.M., and Singer D.E. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46 (1997) 1594-1600
24. Edwards K.L., Burchfiel C.M., Sharp D.S., Curb J.D., Rodriguez B.L., Fujimoto W.Y., et al. Factors of the insulin resistance syndrome in nondiabetic and diabetic elderly Japanese-American men. Am J Epidemiol 147 (1998) 441-447
25. Leyva F., Godsland I.F., Ghatei M., Proudler A.J., Aldis S., Walton C., et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 18 (1998) 928-933
26. Gray R.S., Fabsitz R.R., Cowan L.D., Lee E.T., Howard B.V., and Savage P.J. Risk factor clustering in the insulin resistance syndrome: the Strong Heart Study. Am J Epidemiol 148 (1998) 869-878
27. Leyva F., Godsland I.F., Worthington M., Walton C., and Stevenson J.C. Factors of the metabolic syndrome: baseline interrelationships in the first follow-up cohort of the HDDRISC Study (HDDRISC-1). Heart disease and diabetes risk indicators in a screened cohort. Arterioscler Thromb Vasc Biol 18 (1998) 208-214
28. Chen W., Srinivasan S.R., Elkasabany A., and Berenson G.S. Cardiovascular risk factors clustering features of insulin resistance syndrome (Syndrome X) in a biracial (Black-White) population of children, adolescents, and young adults: the Bogalusa Heart Study. Am J Epidemiol 150 (1999) 667-674
29. Lempiainen P., Mykkanen L., Pyorala K., Laakso M., and Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 100 (1999) 123-128
30. Kekäläinen P., Sarlund H., Pyorala K., and Laakso M. Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. Diabetes Care 22 (1999) 86-92
31. Snehalatha C., Sivasankari S., Satyavani K., Vijay V., and Ramachandran A. Insulin resistance alone does not explain the clustering of cardiovascular risk factors in southern India. Diabet Med 17 (2000) 152-157
32. Chen C.H., Lin K.C., Tsai S.T., and Chou P. Different association of hypertension and insulin-related metabolic syndrome between men and women in 8437 nondiabetic Chinese. Am J Hypertens 13 (2000) 846-853
33. Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia 43 (2000) 148-155
34. Sakkinen P.A., Wahl P., Cushman M., Lewis M.R., and Tracy R.P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152 (2000) 897-907
35. Pyorala M., Miettinen H., Halonen P., Laakso M., and Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 20 (2000) 538-544
36. Shmulewitz D., Auerbach S.B., Lehner T., Blundell M.L., Winick J.D., Youngman L.D., et al. Epidemiology and factor analysis of obesity, type II diabetes, hypertension, and dyslipidemia (syndrome X) on the Island of Kosrae. Federated States of Micronesia. Hum Hered 51 (2001) 8-19
37. Chen W., Srinivasan S.R., and Berenson G.S. Plasma renin activity and insulin resistance in African American and white children: the Bogalusa Heart Study. Am J Hypertens 14 (2001) 212-217
38. Lindblad U., Langer R.D., Wingard D.L., Thomas R.G., and Barrett-Connor E.L. Metabolic syndrome and ischemic heart disease in elderly men and women. Am J Epidemiol 153 (2001) 481-489
39. Maison P., Byrne C.D., Hales C.N., Day N.E., and Wareham N.J. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 24 (2001) 1758-1763
40. Hodge A.M., Boyko E.J., de Courten M., Zimmet P.Z., Chitson P., Tuomilehto J., et al. Leptin and other components of the metabolic syndrome in Mauritius-a factor analysis. Int J Obes Relat Metab Disord 25 (2001) 126-131
41. Hanley A.J., Karter A.J., Festa A., D'Agostino Jr. R., Wagenknecht L.E., Savage P., et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: results form the Insulin Resistance Atherosclerosis Study. Diabetes 51 (2002) 2642-2647
42. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
43. Hanson R.L., Imperatore G., Bennett P.H., and Knowler W.C. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 51 (2002) 3120-3127
44. Arya R., Blangero J., Williams K., Almasy L., Dyer T.D., Leach R.J., et al. Factors of insulin resistance syndrome-related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican-Americans. Diabetes 51 (2002) 841-847
45. Shen B.J., Todaro J.F., Niaura R., McCaffery J.M., Zhang J., Spiro III A., et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 157 (2003) 701-711
46. Ford E.S. Factor analysis and defining the metabolic syndrome. Ethn Dis 13 (2003) 429-437
47. Choi K.M., Lee J., Kim Y.H., Kim K.B., Kim D.L., Kim S.G., et al. Koreans-Southwest Seoul (SWS) Study. Relation between insulin resistance and hematological parameters in elderly Koreans-Southwest Seoul (SWS) Study. Diabetes Res Clin Pract 60 (2003) 205-212
48. Novak S., Stapleton L.M., Litaker J.R., and Lawson K.A. A confirmatory factor analysis evaluation of the coronary heart disease risk factors of metabolic syndrome with emphasis on the insulin resistance factor. Diabetes Obes Metab 5 (2003) 388-396
49. Howard B.V., Criqui M.H., Curb J.D., Rodabough R., Safford M.M., Santoro N., et al. Risk factor clustering in the insulin resistance syndrome and its relationship to cardiovascular disease in postmenopausal white, black, hispanic, and Asian/Pacific Islander women. Metabolism 52 (2003) 362-371
50. Zitzmann M., Gromoll J., von Eckardstein A., and Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 46 (2003) 31-39
51. Tang W., Miller M.B., Rich S.S., North K.E., Pankow J.S., Borecki I.B., et al. National Heart, Lung, and Blood Institute Family Heart Study. Linkage analysis of a composite factor for the multiple metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. Diabetes 52 (2003) 2840-2847
52. Oh J.Y., Hong Y.S., Sung Y.A., and Barrett-Connor E. Prevalence and factor analysis of metabolic syndrome in an urban Korean population. Diabetes Care 27 (2004) 2027-2032
53. Wang J.J., Qiao Q., Miettinen M.E., Lappalainen J., Hu G., and Tuomilehto J. The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a chinese population with high postprandial glucose. Diabetes Care 27 (2004) 2429-2437
54. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350 (2004) 2362-2374
55. Ang L.W., Ma S., Cutter J., Chew S.K., Tan C.E., and Tai E.S. The metabolic syndrome in Chinese. Malays and Asian Indians. Factor analysis of data from the 1998 Singapore National Health Survey. Diabetes Res Clin Pract 67 (2005) 53-62
56. Pladevall M., Singal B., Williams L.K., Brotons C., Guyer H., Sadurni J., et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care 29 (2006) 113-122
57. Meigs J.B. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 152 (2000) 908-911
58. Hanley A.J., Meigs J.B., Williams K., Haffner S.M., and D'Agostino Sr. R.B. (Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol 161 (2005) 1182-1184
59. De Taeye B., Smith L.H., and Vaughan D.E. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 5 (2005) 149-154
60. Liang X., Kanjanabuch T., Mao S.L., Hao C.M., Tang Y.W., Declerck P.J., et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 290 (2006) E103-E113
61. Dandona P., Aljada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
62. Sjoholm A., and Nystrom T. Endothelial inflammation in insulin resistance. Lancet 365 (2005) 610-612
63. Devaraj S., Rosenson R.S., and Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 33 (2004) 431-453
64. Mertens I., Verrijken A., Michiels J.J., Van der Planken M., Ruige J.B., and Van Gaal L.F. Among inflammation and coagulation markers PAI-1 is a true component of the metabolic syndrome. Int J Obes January 3 (2006) [Epub ahead of print]
65. Salmenniemi U., Ruotsalainen E., Pihlajamaki J., Vauhkonen I., Kainulainen S., Punnonen K., et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 110 (2004) 3842-3848
66. Austin M.A., Edwards Kl., McNeely M.J., Chandler W.L., Leonetti D.L., Talmud P.J., et al. Heritability of multivariate factors of the metabolic syndrome in nondiabetic Japanese Americans. Diabetes 53 (2004) 1166-1169
67. Hanley A.J., Festa A., D'Agostino Jr. R.B., Wagenknecht L.E., Savage P.J., Tracy R.P., et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 53 (2004) 1773-1781
68. Sutherland J.P., McKinley B., and Eckel R.H. The metabolic syndrome and inflammation. Metab Syndr Relat Disord 2 (2004) 82-104
69. Han T.S., Sattar N., Williams K., Gonzalez-Villalpando C., Lean M.E., and Haffner S.M. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25 (2002) 2016-2021
70. Ferreira I., Twisk J.W., van Mechelen W., Kemper H.C., and Stehouwer C.D. Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults: the Amsterdam growth and health longitudinal study. Arch Intern Med 165 (2005) 42-48
71. Goodpaster B.H., Krishnaswami S., Harris T.B., Katsiaras A., Kritchevsky S.B., Simonsick E.M., et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 165 (2005) 777-783
72. Del Prato S., Enzi G., Vigili de Kreutzenberg S., Lisato G., Riccio A., Maifreni L., et al. Insulin regulation of glucose and lipid metabolism in massive obesity. Diabetologia 33 (1990) 226-228
73. Unger R.H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144 (2003) 5159-5165
74. Chan D.C., Barrett H.P., and Watts G.F. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs 4 (2004) 227-246
75. Boden G., and Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32 Suppl. 3 (2002) 14-23
76. Poitout V., Briaud I., Kelpe C., and Hagman D. Gluco-lipotoxicity of the pancreatic beta cell. Ann Endocrinol (Paris) 65 (2004) 37-41
77. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003) 1796-1808
78. Di Gregorio G.B., Yao-Borengasser A., Rasouli N., Varma V., Lu T., Miles L.M., et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 54 (2005) 2305-2513
79. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112 (2003) 1821-1830
80. Arner P. Insulin resistance in type 2 diabetes-role of the adipokines. Curr Mol Med 5 (2005) 333-339
81. Utzschneider K.M., Carr D.B., Tong J., Wallace T.M., Hull R.L., Zraika S., et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48 (2005) 2330-2333
82. La Cava A., Alviggi C., and Mararese G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 82 (2004) 4-11
83. Xydakis A.M., Case C.C., Jones P.H., Hoogeveen R.C., Liu M.Y., Smith E.O., et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 89 (2004) 2697-2703
84. Matsushita K., Yatsuya H., Tamakoshi K., Wada K., Otsuka R., Takefuji S., et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol (2006) [Epub ahead of print]
85. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 439-451
86. Ferreira I.A., Mocking A.I., Feijge M.A., Gorter G., van Haeften T.W., Heemskerk J.W., et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26 (2006) 417-422
87. Stern M.P. Strategies and prospects for finding insulin resistance genes. J Clin Invest 106 (2000) 323-327
88. Edwards K.L., Newman B., Mayer E., Selby J.V., Krauss R.M., and Austin M.A. Heritability of factors of the insulin resistance syndrome in women twins. Genet Epidemiol 14 (1997) 241-253
89. Reaven G.M. Banting lecture. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
90. Del Prato S. Pathophysiology of insulin action in humans. In: Serrano Rios M., Caro J.F., Carraro R., and Gutierrez Fuentes (Eds). The metabolic syndrome at the beginning of the XXIst century. A genetic and molecular approach (2005), Elsevier España, Madrid 179-197
91. Hanley A.J., Williams K., Stern M.P., and Haffner S.M. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25 (2002) 1177-1184
92. Bonora E., Formentini G., Calcaterra F., Lombardi S., Marini F., Zenari L., et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25 (2002) 1135-1141